BENSALEM, Pa.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24ZGNX&src=ctag” target=”_blank”gt;$ZGNXlt;/agt; lt;a href=”https://twitter.com/hashtag/classaction?src=hash” target=”_blank”gt;#classactionlt;/agt;–Law Offices of Howard G. Smith reminds investors of the upcoming June
11, 2019 deadline to file a lead plaintiff motion in the class
action filed on behalf of investors who purchased Zogenix, Inc.
(“Zogenix” or the “Company”) (NASDAQ: ZGNX)
securities between February 6, 2019 and April 8, 2019, inclusive
(the “Class Period”).
Investors suffering losses on their Zogenix investments are encouraged
to contact the Law Offices of Howard G. Smith to discuss their legal
rights in this class action at 888-638-4847 or by email to [email protected].
On April 8, 2019, Zogenix announced that it received a refusal to file
letter from the U.S. Food and Drug Administration (“FDA”) regarding
Zogenix’s new drug application (“NDA”) for FINTEPLA, Zogenix’s proposed
treatment for seizures associated with Dravet syndrome. The FDA
determined that the NDA was not sufficiently complete to permit a
substantive review because certain non-clinical studies were not
submitted to allow assessment of the chronic administration of
fenfluramine, and the application contained an incorrect version of a
clinical dataset.
On this news, shares of Zogenix fell $11.89 or nearly 23% to close at
$39.96 per share on April 9, 2019, thereby injuring investors.
The complaint filed in this class action alleges that throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company’s business, operations, and prospects. Specifically,
Defendants failed to disclose to investors: (1) Zogenix’s NDA for
FINTEPLA contained inadequate non-clinical data and an incorrect version
of a clinical dataset; (2) consequently, Zogenix’s NDA for FINTEPLA was
unlikely to gain FDA approval; and (3) as a result, the Company’s public
statements were materially false and misleading at all relevant times.
If you purchased shares of Zogenix during the Class Period you may move
the Court no later than June 11, 2019 to ask the Court
to appoint you as lead plaintiff if you meet certain legal requirements.
To be a member of the class action you need not take any action at this
time; you may retain counsel of your choice or take no action and remain
an absent member of the class action. If you wish to learn more about
this class action, or if you have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Howard G. Smith, Esquire, of Law Offices of Howard G.
Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by
telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected],
or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com
